An overview of prevalence, determinants and health outcomes of polypharmacy

被引:212
|
作者
Khezrian, Mina [1 ]
McNeil, Chris J. [1 ]
Murray, Alison D. [1 ]
Myint, Phyo K. [2 ]
机构
[1] Univ Aberdeen, Inst Med Sci, Lilian Sutton Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland
[2] Univ Aberdeen, Inst Appl Hlth Sci, Foresterhill, Aberdeen, Scotland
关键词
health outcome; multimorbidity; older adults; polypharmacy; DWELLING OLDER MEN; ANTICHOLINERGIC BURDEN; CLINICAL CONSEQUENCES; DRUG-USE; FRAILTY; ADULTS; RISK; MORTALITY; CARE; EPIDEMIOLOGY;
D O I
10.1177/2042098620933741
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A high rate of polypharmacy is, in part, a consequence of the increasing proportion of multimorbidity in the ageing population worldwide. Our understanding of the potential harm of taking multiple medications in an older, multi-morbid population, who are likely to be on a polypharmacy regime, is limited. This is a narrative literature review that aims to appraise and summarise recent studies published about polypharmacy. We searched MEDLINE using the search termspolypharmacy(and its variations, e.g. multiple prescriptions, inappropriate drug use, etc.) in titles. Systematic reviews and original studies in English published between 2003 and 2018 were included. In this review, we provide current definitions of polypharmacy. We identify the determinants and prevalence of polypharmacy reported in different studies. Finally, we summarise some of the findings regarding the association between polypharmacy and health outcomes in older adults, with a focus on frailty, hospitalisation and mortality. Polypharmacy was most often defined in terms of the number of medications that are being taken by an individual at any given time. Our review showed that the prevalence of polypharmacy varied between 10% to as high as around 90% in different populations. Chronic conditions, demographics, socioeconomics and self-assessed health factors were independent predictors of polypharmacy. Polypharmacy was reported to be associated with various adverse outcomes after adjusting for health conditions. Optimising care for polypharmacy with valid, reliable measures, relevant to all patients, will improve the health outcomes of older adult population.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Determinants of health and pregnancy and birth outcomes: an overview
    Falcone, V
    Nistico, F.
    De Luca, A.
    Arniani, S.
    Messina, G.
    Nante, N.
    D'Urso, A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2024, 34
  • [2] Global evidence on obesity and related outcomes: An overview of prevalence, trends, and determinants
    Doytch N.
    Dave D.M.
    Kelly I.R.
    Eastern Economic Journal, 2016, 42 (1) : 7 - 28
  • [3] Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study
    Julien Castioni
    Pedro Marques-Vidal
    Nazanin Abolhassani
    Peter Vollenweider
    Gérard Waeber
    BMC Health Services Research, 17
  • [4] Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study
    Castioni, Julien
    Marques-Vidal, Pedro
    Abolhassani, Nazanin
    Vollenweider, Peter
    Waeber, Gerard
    BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [5] An overview of the commercial determinants of health
    Melissa Mialon
    Globalization and Health, 16
  • [6] An overview of the commercial determinants of health
    Mialon, Melissa
    GLOBALIZATION AND HEALTH, 2020, 16 (01)
  • [7] THE PREVALENCE AND DETERMINANTS OF POLYPHARMACY: DATA FROM THE BRITISH 1946 BIRTH COHORT
    Rawle, M. J.
    Moore, A. G.
    Richards, M.
    Kuh, D.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2017, 71 : A73 - A74
  • [8] The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
    Rawle, Mark James
    Richards, Marcus
    Davis, Daniel
    Kuh, Diana
    BMC GERIATRICS, 2018, 18
  • [9] The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
    Mark James Rawle
    Marcus Richards
    Daniel Davis
    Diana Kuh
    BMC Geriatrics, 18
  • [10] PSYCHOTROPIC POLYPHARMACY IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH MENTAL DISORDERS: PREVALENCE AND DETERMINANTS
    Medhekar, R.
    Fujimoto, K.
    Aparasu, R. R.
    Bhatara, V
    Johnson, M. L.
    Alonzo, J.
    Schwarzwald, H.
    Chen, H.
    VALUE IN HEALTH, 2017, 20 (05) : A294 - A294